GILD vs. WST: Gilead Sciences vs. West Pharmaceutical Services Stock Comparison

Company Profile

Gilead Sciences (GILD) and West Pharmaceutical Services (WST) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but GILD is classified in Biotechnology while WST is classified in Life Sciences Tools & Services.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Gilead Sciences (GILD) reports a negative ROE of -22.45%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile West Pharmaceutical Services (WST) reports 21.23%, ranking against industry peers normally.

Gilead Sciences (GILD) reports a negative net margin of -12.46%, usually indicating a net loss over the period. Meanwhile West Pharmaceutical Services (WST) reports 18.81%, ranking against industry peers normally.

Both Gilead Sciences (GILD) at 42.43% and West Pharmaceutical Services (WST) at 25.37% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Gilead Sciences (GILD) at 2.39% and West Pharmaceutical Services (WST) at 6.25% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Gilead Sciences (GILD) at 1,684.21% clears its industry range for EPS growth, a much stronger earnings trajectory than West Pharmaceutical Services (WST) at 1.49%, which is closer to a typical peer reading.

Growth Metrics

Financial Strength

West Pharmaceutical Services (WST) at 2.82 keeps current ratio within its industry’s typical mid-range, while Gilead Sciences (GILD) at 1.38 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for GILD.

West Pharmaceutical Services (WST) at 0.11 is near its industry mid-range for debt-to-equity ratio, while Gilead Sciences (GILD) at 2.02 sits above its benchmark range, pointing to a heavier debt load relative to equity.

Financial Strength Metrics

Dividends

Both Gilead Sciences (GILD) at 1.94% and West Pharmaceutical Services (WST) at 0.22% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

Both Gilead Sciences (GILD) at 43.46% and West Pharmaceutical Services (WST) at 9.88% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: West Pharmaceutical Services (WST) trades at 44.87 times trailing earnings, ranked against its peers, while Gilead Sciences (GILD) has no P/E ratio this period.

On P/S ratio, both Gilead Sciences (GILD) at 6.68 and West Pharmaceutical Services (WST) at 8.20 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Both look rich against book: West Pharmaceutical Services (WST) at 9.40 sits in the upper P/B ratio quartile, and Gilead Sciences (GILD) at 15.88 prices even higher, above its industry range.

Valuation Metrics